The triazole drug fluconazole remains one of the most commonly prescribed antifungal drugs, both for prophylaxis in high-risk patients and also as a second-line treatment option for invasive Candida infections. Established susceptibility profiles and clinical interpretive breakpoints are available for fluconazole with Candida albicans , Candida glabrata , Candida tropicalis , and Candida parapsilosis , which account for the majority of infections due to pathogenic yeast species.